The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma
During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasm...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1988-01, Vol.35 (2), p.187-193 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 193 |
|---|---|
| container_issue | 2 |
| container_start_page | 187 |
| container_title | European journal of clinical pharmacology |
| container_volume | 35 |
| creator | LOOS, U MUSCH, E ENGEL, M HARTLAPP, J. H HÜGL, E DENGLER, H. J |
| description | During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy. |
| doi_str_mv | 10.1007/BF00609251 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78533656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78533656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-f8c7bdb148f5d8bc46e2ab7a9d2028857e0d6abf509243c455329e7c410ce19a3</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMo67p68S70IB6E6kzTNO1RF79gQYT1XNJ06kb7ZZIe9t9b3bKeBuZ9eJl5GDtHuEEAeXv_CJBAFgk8YHOMeRQixHjI5gAcwySTcMxOnPsEQJEBn7EZxwwzLufsbb2hoN8o2yjdfZmWvNEu6KqgoXpc16oNysGa9iMwrSfbGO-p9YHfkFX99g8cam_6moJmS3XXqFN2VKna0dk0F-z98WG9fA5Xr08vy7tVqDmiD6tUy6IsME4rUaaFjhOKVCFVVkYQpamQBGWiikqMf8Vcx0LwKCOpYwRNmCm-YFe73t523wM5nzfGaarHk6kbXC5TwXkikhG83oHads5ZqvLemkbZbY6Q__rL__2N8MXUOhQNlXt0Ejbml1OunFZ1ZVWrjdtjEmPBRcR_AFMSd8Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78533656</pqid></control><display><type>article</type><title>The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>LOOS, U ; MUSCH, E ; ENGEL, M ; HARTLAPP, J. H ; HÜGL, E ; DENGLER, H. J</creator><creatorcontrib>LOOS, U ; MUSCH, E ; ENGEL, M ; HARTLAPP, J. H ; HÜGL, E ; DENGLER, H. J</creatorcontrib><description>During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00609251</identifier><identifier>PMID: 3191937</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Administration, Oral ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Female ; Half-Life ; Humans ; Injections, Intravenous ; Male ; Medical sciences ; Melphalan - administration & dosage ; Melphalan - blood ; Melphalan - pharmacokinetics ; Metabolic Clearance Rate ; Middle Aged ; Multiple Myeloma - drug therapy ; Multiple Myeloma - metabolism ; Pharmacology. Drug treatments ; Prednisone - administration & dosage ; Prednisone - blood ; Prednisone - pharmacokinetics</subject><ispartof>European journal of clinical pharmacology, 1988-01, Vol.35 (2), p.187-193</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-f8c7bdb148f5d8bc46e2ab7a9d2028857e0d6abf509243c455329e7c410ce19a3</citedby><cites>FETCH-LOGICAL-c311t-f8c7bdb148f5d8bc46e2ab7a9d2028857e0d6abf509243c455329e7c410ce19a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7145352$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3191937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LOOS, U</creatorcontrib><creatorcontrib>MUSCH, E</creatorcontrib><creatorcontrib>ENGEL, M</creatorcontrib><creatorcontrib>HARTLAPP, J. H</creatorcontrib><creatorcontrib>HÜGL, E</creatorcontrib><creatorcontrib>DENGLER, H. J</creatorcontrib><title>The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melphalan - administration & dosage</subject><subject>Melphalan - blood</subject><subject>Melphalan - pharmacokinetics</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - blood</subject><subject>Prednisone - pharmacokinetics</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhoMo67p68S70IB6E6kzTNO1RF79gQYT1XNJ06kb7ZZIe9t9b3bKeBuZ9eJl5GDtHuEEAeXv_CJBAFgk8YHOMeRQixHjI5gAcwySTcMxOnPsEQJEBn7EZxwwzLufsbb2hoN8o2yjdfZmWvNEu6KqgoXpc16oNysGa9iMwrSfbGO-p9YHfkFX99g8cam_6moJmS3XXqFN2VKna0dk0F-z98WG9fA5Xr08vy7tVqDmiD6tUy6IsME4rUaaFjhOKVCFVVkYQpamQBGWiikqMf8Vcx0LwKCOpYwRNmCm-YFe73t523wM5nzfGaarHk6kbXC5TwXkikhG83oHads5ZqvLemkbZbY6Q__rL__2N8MXUOhQNlXt0Ejbml1OunFZ1ZVWrjdtjEmPBRcR_AFMSd8Y</recordid><startdate>19880101</startdate><enddate>19880101</enddate><creator>LOOS, U</creator><creator>MUSCH, E</creator><creator>ENGEL, M</creator><creator>HARTLAPP, J. H</creator><creator>HÜGL, E</creator><creator>DENGLER, H. J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19880101</creationdate><title>The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma</title><author>LOOS, U ; MUSCH, E ; ENGEL, M ; HARTLAPP, J. H ; HÜGL, E ; DENGLER, H. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-f8c7bdb148f5d8bc46e2ab7a9d2028857e0d6abf509243c455329e7c410ce19a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melphalan - administration & dosage</topic><topic>Melphalan - blood</topic><topic>Melphalan - pharmacokinetics</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - blood</topic><topic>Prednisone - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LOOS, U</creatorcontrib><creatorcontrib>MUSCH, E</creatorcontrib><creatorcontrib>ENGEL, M</creatorcontrib><creatorcontrib>HARTLAPP, J. H</creatorcontrib><creatorcontrib>HÜGL, E</creatorcontrib><creatorcontrib>DENGLER, H. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LOOS, U</au><au>MUSCH, E</au><au>ENGEL, M</au><au>HARTLAPP, J. H</au><au>HÜGL, E</au><au>DENGLER, H. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1988-01-01</date><risdate>1988</risdate><volume>35</volume><issue>2</issue><spage>187</spage><epage>193</epage><pages>187-193</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>3191937</pmid><doi>10.1007/BF00609251</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1988-01, Vol.35 (2), p.187-193 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78533656 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Female Half-Life Humans Injections, Intravenous Male Medical sciences Melphalan - administration & dosage Melphalan - blood Melphalan - pharmacokinetics Metabolic Clearance Rate Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Pharmacology. Drug treatments Prednisone - administration & dosage Prednisone - blood Prednisone - pharmacokinetics |
| title | The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A16%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pharmacokinetics%20of%20melphalan%20during%20intermittent%20therapy%20of%20multiple%20myeloma&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=LOOS,%20U&rft.date=1988-01-01&rft.volume=35&rft.issue=2&rft.spage=187&rft.epage=193&rft.pages=187-193&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00609251&rft_dat=%3Cproquest_cross%3E78533656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78533656&rft_id=info:pmid/3191937&rfr_iscdi=true |